Firm gains access to dotLab and will increase the number of biomarker assays that work with it.
The Institute of Bioanalytics (IBA) has purchased Axela’s assay-development platform, dotLab. IBA thus expands its contract assay development business such that customers will now have access to single or multiplexed immunoassays.
In addition to custom assay development, IBA is partnering with Axela to expand the menu of biomarker assays optimized for use with the dotLab platform and the soon-to-be available panelPlus Sensors. This technology is being designed to be able combine preconfigured assays with novel markers to enhance validation activities.
Benefits of the dotLab System include extended dynamic range, simultaneous measurement of high- and low-abundance markers, and concurrent detection of secondary information such as binding partners, isotype, and avidity, according to the companies.
